Novavax, Inc. - Common Stock (NQ:NVAX)

11.79 +1.32 (+12.67%)

Delayed Quote Updated: 1:46 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

68 69 Next >

Why Novavax Stock Is Seeing Blue Skies ↗

April 06, 2023

Novavax Inc (NASDAQ: NVAX) shares are trading higher by 9.88% to $8.34 Thursday afternoon. The stock may be reacting to the company's presentations at the 2023 World Vaccine Congress this week.

Via Benzinga

Short Interest Sector Focus: Healthcare Sector ↗

April 04, 2023

As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

1 Stock to Buy and 1 to Avoid Before the Next Bull Market ↗

April 04, 2023

These stocks could move in opposite directions come the next bull market.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 03, 2023

Via Benzinga

7 ‘Fallen Angel’ Stocks to Sell Before They Plummet Again ↗

April 02, 2023

These seven stocks to sell have already become out of favor among investors, but that doesn't mean they can't sink further from here.

Via InvestorPlace

Why Novavax Stock Slipped on Thursday ↗

March 23, 2023

The biotech makes it official: One of its leaders is stepping down.

Via The Motley Fool

1 Green Flag and 1 Red Flag for Novavax ↗

March 18, 2023

Novavax shares have dropped more than 90% over the past year.

Via The Motley Fool

This Growth Stock Is Down 90%. Is It Time to Sell or Buy? ↗

March 12, 2023

Think twice about picking up shares of Novavax, even if you're brave.

Via The Motley Fool

COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All ↗

March 31, 2023

Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many...

Via Benzinga

1 Growth Stock With 741% Upside, According to Wall Street ↗

March 30, 2023

The vaccine maker has delivered returns of this size before, but things have changed a lot since.

Via The Motley Fool

Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze ↗

March 27, 2023

Short squeeze stocks are all over Wall Street in the wake of the regional banking crisis. Which names should you keep an eye out for?

Via InvestorPlace

3 Stocks That Won’t Survive a Major Market Crash ↗

March 23, 2023

These three stocks appear to be particularly exposed to a potential market crash, and should be on investors' sell lists right now.

Via InvestorPlace

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

March 20, 2023

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

Via News Direct

Topics Death Economy

1 Stock You Need to Sell Before the Next Bull Market ↗

March 11, 2023

Freeing up your capital now is preferable to losing more of it on this stock.

Via The Motley Fool

Why Is Novavax (NVAX) Stock Up 12% Today? ↗

March 03, 2023

Although Novavax may have seen its shares pop higher on Friday, investors should consider the bigger picture of NVAX stock.

Via InvestorPlace

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

March 20, 2023

By Ernest Dela Aglanu, Benzinga

Via TheNewswire.com

Topics Death Economy

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats ↗

March 20, 2023

With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and...

Via Benzinga

2 Growth Stocks That Are Trading at a Huge Discount Right Now -- Maybe Rightfully So ↗

March 16, 2023

Focus on the prospects for their business, not their valuations.

Via The Motley Fool

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves ↗

March 14, 2023

The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. They'll soon need new sources of revenue.

Via InvestorPlace

Novavax Stock: Bear vs. Bull ↗

March 10, 2023

The stock has brought investors eye-popping gains and losses over the past few years.

Via The Motley Fool

Why Novavax Stock Was Down in the Dumps This Week ↗

March 03, 2023

Investors were disappointed yet again with the vaccine company's quarterly earnings and forward guidance.

Via The Motley Fool

Novavax Just Dropped a Bombshell on Investors: Even Management Is Questioning Its Future ↗

March 08, 2023

Can Novavax survive the year?

Via The Motley Fool

FDA's Regulatory Delay is The Reason For Novavax, Lucira Health's Failure: WSJ Report ↗

March 07, 2023

Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb

Via Benzinga

US Stocks Could Consolidate As S&P 500, Nasdaq Futures Tick Up Ahead Of Fed Chair Powell's Congressional Testimony ↗

March 06, 2023

Stocks could pause on Monday after returning to winning ways in the past week, as the focus shifts to Fed Chair Jerome Powell’s two-day Congressional testimony this week. Cues From Last Week’s...

Via Benzinga

Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 06, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Benzinga Bulls And Bears: Tesla, Microsoft, Apple, Novavax And Why Dogecoin May Be Poised For 50% Surge ↗

March 04, 2023

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Should You Give Up on Novavax? ↗

March 03, 2023

After a spectacular 2020 performance, Novavax's shares have plummeted.

Via The Motley Fool

Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review ↗

March 03, 2023

Many leaders flashed buy signals as the indexes rebounded from support.

Via Investor's Business Daily

Nasdaq, S&P Futures Slide As Bond Yields Stay Above 4%: Economic Signals Ominous But Don't Panic Yet, Says Analyst ↗

March 02, 2023

The mood on Wall Street continues to be somber on Thursday, as risk aversion continues to rule high. Some positive earnings could serve to cushion any potential slide even as traders look ahead to the...

Via Benzinga

S&P 500 Drops For Second Session In A Row; Volatility In Markets Decreases ↗

March 02, 2023

The S&P 500 dropped for the second consecutive session on Wednesday following the release of manufacturing data. The yield on 10-year notes surpasses 4% for the first time since November, after the ISM...

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.